This Healthcare Stock Could Be One of the Best Companies to Own in 2026

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) generated $24.8 billion in revenue through the first nine months of 2025 and has overtaken Keytruda as the world's top-selling drug, with some analysts projecting ~ $62 billion in sales by 2030. The company continues to post industry-leading clinical results — orforglipron is under regulatory review with a shortened review voucher and retatrutide produced a mean weight loss of 28.7% at the highest dose in phase 3 — supporting market leadership versus rivals like Novo Nordisk, Amgen and Pfizer. Despite a premium forward P/E of 33 (sector avg. 18.2), a PEG of ~0.98 underpins the thesis that strong revenue and earnings growth justify the valuation, bolstering Eli Lilly's near- and mid-term growth outlook.

Analysis

Market structure: LLY is the clear near-term winner (tirzepatide = $24.8bn YTD; street projects ~$62bn by 2030), plus contract manufacturers and specialty pharmacies that scale supply; competitors (NVO, AMGN, PFE) face share pressure but can still gain in adjacent niches. Pricing power is strong now but will face downward pressure as oral competitors and new peptides arrive; demand appears to outstrip supply through 2026, supporting >20% revenue growth assumptions near-term. Cross-asset: stronger LLY fundamentals support tighter corporate credit spreads vs. peers, higher implied volatility in equity options, and modest US-dollar strength on risk-adjusted healthcare outperformance; commodity impact is negligible.

Risk assessment: Tail risks include FDA safety/regulatory restrictions, aggressive PBM formulary limits, or manufacturing bottlenecks that could cut tirzepatide growth by >30% versus forecasts; antitrust/patent litigation is medium-probability. Immediate (days) risk: catalyst-driven IV spikes around approvals (orforglipron end-Feb); short-term (weeks/months): quarterly sales cadence and reimbursement decisions; long-term (years): patent cliffs and cheaper entrants. Hidden dependencies: CMO capacity, EU/China reimbursement timelines, and PBM rebate negotiations can materially slow uptake.

Trade implications: Direct play — establish a core long in LLY sized 2–4% of portfolio and scale to 6% if quarterly tirzepatide sales exceed $8bn (any quarter) or guidance raises by >10%. Pair trade — long LLY vs short AMGN (or PFE) sized 3:2 over 12–24 months to isolate GLP-1 share gains. Options — buy call spreads (LLY Jan 2028 LEAP buy ATM/sell 20% OTM) sized 0.5–1% as a low-cost leveraged upside; buy short-dated (90-day) call spreads ahead of Feb/Mar catalysts for 0.25–0.5% exposure. Sector rotation — overweight Healthcare by +5% vs. benchmark, funded by trimming Consumer Discretionary.

Contrarian angles: Consensus underestimates PBM and insurer resistance: if payers impose step therapy or limit duration, peak sales could be 20–40% below current street assumptions. The market may be underpricing the probability of regulatory labeling changes after wider population use; historical parallels include rapid hype cycles (PCSK9, SGLT2) followed by reimbursement recalibrations. Mispricing threshold: if tirzepatide quarterly growth falls below 20% QoQ or guidance is cut by >10% next two quarters, re-rate LLY to broader healthcare multiple (forward P/E <25).

Key Decisions for Investors

• Establish a 3% portfolio long in Eli Lilly (LLY) over the next 2 weeks; scale to 6% if any future quarter posts tirzepatide sales > $8bn or management raises FY guidance by >10%; set a stop-trim to 1.5% if shares drop >15% in 30 days on no fundamental guidance change.
• Implement a 12–24 month pair trade: long LLY (3% weight) / short AMGN (2% weight) to express GLP-1 share capture; unwind if the long/short performance spread narrows by >15% or if AMGN launches a clearly superior clinical candidate.
• Deploy option leverage: buy LLY Jan 2028 call spread (buy ATM, sell ~20% OTM) sized 0.5% of portfolio for asymmetric upside tied to pipeline upside; additionally buy 90-day call spreads (0.25% size) ahead of Feb–Mar 2026 regulatory readouts to capture short-term IV moves.
• Hedge policy/reimbursement risk: if PBM/formulary restrictions or a major FDA safety communication occur within 90 days, reduce LLY exposure to 1% and rotate proceeds into defensive healthcare (JNJ or multi-product PFE stake) until clarity; monitor PBM bulletin and CMS reimbursement updates weekly.